News by Subject Medicine & Health

A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity of post-treatment surveillance and detection of recurrence or overall survival (OS) in patients with stage I, II or III colorectal cancer (CRC). Published in the Journal of the American Medical Association, the study is the largest of surveillance intensity in CRC ever conducted.

A cancer patient with advanced ovarian cancer had a 'remarkable' journey to recovery that may be partially attributed to a treatment she received for a completely different disease, according to a case report published in ecancermedicalscience.

Ingestion of a blue dye tablet during bowel prep for colonoscopy could be a significant advance in the early detection of colorectal cancer (CRC). When used in conjunction with colonoscopy, the blue dye increased adenoma detection rate (ADR) by nearly 9 percent, according to a study scheduled for presentation at Digestive Disease Week® (DDW) 2018.

Combining a DNA vaccine, which boosts the body's immune response against tumors, with an antibody that blocks the body's natural defense against the potency of the DNA vaccine, may lead to the development of an effective treatment for late stage colorectal cancer, when a cure is not often possible. Preliminary research leading up to this trial will be presented at Digestive Disease Week® 2018.

Two studies and a related editorial examined the effect of more or less frequent follow-up testing after treatment or surgery for colorectal cancer.

Overall cancer death rates continue to decline in men, women, and children in the United States in all major racial and ethnic groups. Overall cancer incidence, or rates of new cancers, decreased in men and were stable in women from 1999 to 2014. In a companion study, researchers reported an increase in incidence of late-stage prostate cancer and that prostate cancer mortality has stabilized after decades of decline.

In a recent study published in the Journal of Clinical Investigation, Mayo Clinic researchers identified that an FDA drug approved for myelodysplastic syndrome may be useful to treat triple-negative breast cancer, which is one of the most aggressive and lethal types of breast cancer.

Portland State University researchers who published an article three years ago in the New England Journal of Medicine about the presence of previously undiscovered forms of formaldehyde in e-cigarette vapor revisited their research and found that formaldehyde risks were even higher than they originally thought.

A collaborative research team has uncovered new information that more accurately explains how cancerous tumors grow within the body. This study is currently available in Nature Genetics.